Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent Technologies (NYSE: A) announced that CEO Mike McMullen and CFO Bob McMahon will present at the Goldman Sachs Healthcare CEOs Unscripted Conference on January 5, 2023, at 2:05 p.m. ET, and the J.P. Morgan Healthcare Conference on January 10, 2023, at 9:00 a.m. PT. Both events will be webcasted live, accessible via Agilent's Investor Relations website. Agilent is recognized as a leader in the life sciences and diagnostics fields, generating $6.85 billion in revenue in fiscal 2022 and employing 18,000 people globally.
Agilent Technologies (NYSE: A) has received FDA approval for the Resolution ctDx FIRST, a liquid biopsy companion diagnostic to identify advanced non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations who may benefit from KRAZATI (adagrasib). This marks the first FDA-approved liquid biopsy NGS assay as a CDx for KRAZATI. The assay provides broad genomic profiling on 109 genes, facilitating treatment decisions for approximately 14% of NSCLC patients with KRAS mutations and 32% with EGFR mutations. The minimally invasive approach allows for faster diagnostics, benefiting patient care.
Summary not available.
Agilent Technologies Inc. has opened a new Customer Experience Center (CEC) in Lexington, Massachusetts, aimed at enhancing customer education in genomics and diagnostics. This facility will act as a hub for hands-on training, product demonstrations, and workflow solutions, catering to a growing base of pathologists, clinicians, and researchers. The CEC's strategic location ensures accessibility for a high concentration of Agilent's customers. The company generated $6.85 billion in revenue in fiscal 2022, underlining its significant market presence.
Agilent Technologies (NYSE: A) has become the first 'Angel' level sponsor of My Green Lab, enhancing its support for laboratory sustainability. This partnership allows Agilent to access strategic insights to aid customers in achieving sustainability goals. The company also sponsors the Green Lab Certification program, which promotes best practices in lab sustainability. Agilent's labs in Germany, the UK, and Santa Clara have achieved the highest certification level. This initiative aligns with Agilent's commitment to environmental and social governance (ESG) standards.
Agilent Technologies (NYSE: A) has announced the deployment of its Insight200M liquid explosive detection system at London Heathrow airport, enhancing airport security and efficiency. This advanced system, compliant with ECAC standards, improves passenger throughput with a low false alarm rate. The technology aligns with Heathrow's shift to computed tomography X-ray screening, aiming to simplify security processes while maintaining safety. The Insight200M system is a continuation of a partnership dating back to 2013, with minimal operational disruption during deployment.
Agilent Technologies Inc. (NYSE: A) announced a 7% increase in its quarterly dividend to 22.5 cents per share, payable on January 25, 2023, to shareholders on record as of January 3, 2023. This decision reflects the company's strong performance, having generated $6.32 billion in revenue in fiscal 2021. Future dividends will be decided by Agilent's board of directors, subject to risks and uncertainties outlined in their SEC filings.
Agilent Technologies Inc. (NYSE: A) will present at the 5th Annual Evercore ISI HealthCONx conference on November 30 at 10:50 a.m. PST. CEO Mike McMullen and CFO Bob McMahon will lead the presentation. A live webcast and audio archive will be available on Agilent's Investor Relations website. Agilent is a global leader in life sciences and diagnostics, generating $6.32 billion in revenue in 2021, with a workforce of 17,000 employees worldwide. For more information, visit www.agilent.com.
Summary not available.
Agilent Technologies Inc. (NYSE: A) has joined the How2Recycle program, a standardized labeling initiative for recycling packaging. This move aims to enhance customer awareness regarding the proper disposal of Agilent's product packaging. The standardized labels will eliminate confusion about recyclability, showcasing Agilent's commitment to sustainable packaging. The company also emphasizes its goals aligned with Net Zero Carbon and actively participates in My Green Lab. In fiscal 2021, Agilent generated a revenue of $6.32 billion and employs approximately 17,000 people.